Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre

Desai, Anuja; Desai, Parth; Mehta, Jigar; Sachora, Wasimahmed; Bharti, Neeraj; Patel, Tushar; Sukhwani, Kalpesh; Jain, Ankita; Sorathiya, Dipesh; Nanda, Vivek; Mehta, Parin; Desai, Adit

doi:10.1016/j.ijid.2021.10.032

Cited by 5 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, another retrospective cohort study conducted in Brazil reported the reduction in hospital stays and the need for mechanical ventilation in infected health care workers vaccinated with Oxford-AstraZeneca (ChAdOx1) or Corona vac [79]. Similar studies conducted elsewhere have shown the efficacy of vaccines in reducing the severity of COVID-19 and the length of hospital stay [80][81][82][83][84]. Similar to other studies, our study also shows a reduction in hospital stay by four days in fully vaccinated patients compared to unvaccinated patients indicating the efficacy of the COVISHIELD vaccine.…”

Section: Discussionmentioning

confidence: 84%

Assessment of Clinical Profile and Treatment Outcome in Vaccinated and Unvaccinated SARS-CoV-2 Infected Patients

et al. 2022

View full text Add to dashboard Cite

Vaccines against severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) infection, which causes coronavirus disease–19 (COVID-19) in humans, have been developed and are being tested for safety and efficacy. We conducted the cross-sectional prospective cohort study on 820 patients who were positive for SARS-CoV-2 and were admitted to Princess Krishnajammanni trauma care centre (PKTCC), Mysore, which was converted to a designated COVID hospital between April 2021 to July 2021. After obtaining the informed consent, RT-PCR report, vaccination certificate and patient history, patients were classified according to their vaccination status. Results from the study showed decreases in serum ferritin levels, clinical symptoms, improvement in oxygen saturation, early recovery in patients having diabetes and hypertension, and a substantial reduction in the overall duration of hospital stay in vaccinated patients compared to unvaccinated patients. Further, fully vaccinated patients showed better outcomes compared to single dose vaccinated and nonvaccinated patients. Taken together, our findings reaffirm the vaccine’s effectiveness in reducing case fatality and promoting faster recovery compared to nonvaccinated patients. Efforts to increase the number of immunized subjects in the community help to achieve herd immunity and offer protection against the severity of COVID-19 and associated complications while minimizing the public health and economic burden.

show abstract

Section: Discussionmentioning

confidence: 84%

Assessment of Clinical Profile and Treatment Outcome in Vaccinated and Unvaccinated SARS-CoV-2 Infected Patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7][8][9] However, precise analyses of the preventing role of vaccination on intensive care unit (ICU) admission for severe COVID-19 and a detailed description of vaccinated COVID-19 patients who are critically ill are still lacking. [11][12][13][14] Two multicenter studies conducted in Spain and Switzerland reported that fully vaccinated patients with COVID-19 admitted to an ICU had more comorbidities, greater exposure to immunosuppressive drugs, lower ICU length of stay but similar ICU mortality compared with unvaccinated patients. 15,16 However, in both studies, the number of vaccinated and unvaccinated patients admitted during the Alpha and Delta variant waves may have been unbalanced.…”

Section: Introductionmentioning

confidence: 99%

“…Growing evidence supports the safety and efficacy of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to prevent hospitalization and death related to COVID-19 . However, precise analyses of the preventing role of vaccination on intensive care unit (ICU) admission for severe COVID-19 and a detailed description of vaccinated COVID-19 patients who are critically ill are still lacking …”

Section: Introductionmentioning

confidence: 99%

Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy

et al. 2022

View full text Add to dashboard Cite

ImportanceData on the association of COVID-19 vaccination with intensive care unit (ICU) admission and outcomes of patients with SARS-CoV-2–related pneumonia are scarce.ObjectiveTo evaluate whether COVID-19 vaccination is associated with preventing ICU admission for COVID-19 pneumonia and to compare baseline characteristics and outcomes of vaccinated and unvaccinated patients admitted to an ICU.Design, Setting, and ParticipantsThis retrospective cohort study on regional data sets reports: (1) daily number of administered vaccines and (2) data of all consecutive patients admitted to an ICU in Lombardy, Italy, from August 1 to December 15, 2021 (Delta variant predominant). Vaccinated patients received either mRNA vaccines (BNT162b2 or mRNA-1273) or adenoviral vector vaccines (ChAdOx1-S or Ad26.COV2). Incident rate ratios (IRRs) were computed from August 1, 2021, to January 31, 2022; ICU and baseline characteristics and outcomes of vaccinated and unvaccinated patients admitted to an ICU were analyzed from August 1 to December 15, 2021.ExposuresCOVID-19 vaccination status (no vaccination, mRNA vaccine, adenoviral vector vaccine).Main Outcomes and MeasuresThe incidence IRR of ICU admission was evaluated, comparing vaccinated people with unvaccinated, adjusted for age and sex. The baseline characteristics at ICU admission of vaccinated and unvaccinated patients were investigated. The association between vaccination status at ICU admission and mortality at ICU and hospital discharge were also studied, adjusting for possible confounders.ResultsAmong the 10 107 674 inhabitants of Lombardy, Italy, at the time of this study, the median [IQR] age was 48 [28-64] years and 5 154 914 (51.0%) were female. Of the 7 863 417 individuals who were vaccinated (median [IQR] age: 53 [33-68] years; 4 010 343 [51.4%] female), 6 251 417 (79.5%) received an mRNA vaccine, 550 439 (7.0%) received an adenoviral vector vaccine, and 1 061 561 (13.5%) received a mix of vaccines and 4 497 875 (57.2%) were boosted. Compared with unvaccinated people, IRR of individuals who received an mRNA vaccine within 120 days from the last dose was 0.03 (95% CI, 0.03-0.04; P &lt; .001), whereas IRR of individuals who received an adenoviral vector vaccine after 120 days was 0.21 (95% CI, 0.19-0.24; P &lt; .001). There were 553 patients admitted to an ICU for COVID-19 pneumonia during the study period: 139 patients (25.1%) were vaccinated and 414 (74.9%) were unvaccinated. Compared with unvaccinated patients, vaccinated patients were older (median [IQR]: 72 [66-76] vs 60 [51-69] years; P &lt; .001), primarily male individuals (110 patients [79.1%] vs 252 patients [60.9%]; P &lt; .001), with more comorbidities (median [IQR]: 2 [1-3] vs 0 [0-1] comorbidities; P &lt; .001) and had higher ratio of arterial partial pressure of oxygen (Pao2) and fraction of inspiratory oxygen (FiO2) at ICU admission (median [IQR]: 138 [100-180] vs 120 [90-158] mm Hg; P = .007). Factors associated with ICU and hospital mortality were higher age, premorbid heart disease, lower Pao2/FiO2 at ICU admission, and female sex (this factor only for ICU mortality). ICU and hospital mortality were similar between vaccinated and unvaccinated patients.Conclusions and RelevanceIn this cohort study, mRNA and adenoviral vector vaccines were associated with significantly lower risk of ICU admission for COVID-19 pneumonia. ICU and hospital mortality were not associated with vaccinated status. These findings suggest a substantial reduction of the risk of developing COVID-19–related severe acute respiratory failure requiring ICU admission among vaccinated people.

show abstract

“…30 Accordingly, the importance of vaccination is more highlighted in light of lowering the length of hospital and ICU stay and decreasing the burden on economic and human resources. Desai et al 31 possible. 33 The present data revealed that the fully vaccinated patients aged above 65 years had a 24% higher probability of ICU discharge compared with the unvaccinated patients of the same age group.…”

Section: Discussionmentioning

confidence: 97%

“…Accordingly, the importance of vaccination is more highlighted in light of lowering the length of hospital and ICU stay and decreasing the burden on economic and human resources. Desai et al 31 stated that the length of hospital and ICU stay in vaccinated patients was significantly shorter than that in the unvaccinated patients. This finding was in contrast with those declared by Sevinc et al, 8 who reported no difference.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran

Jamaati

Karimi

Ghorbani

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Various severe acute respiratory syndrome coronavirus 2 vaccines with different platforms have been administered worldwide; however, their effectiveness in critical cases of COVID‐19 has remained a concern. In this national cohort study, 24 016 intensive care unit (ICU) coronavirus disease‐2019 (COVID‐19) admissions were included from January to April 2022. The mortality and length of ICU stay were compared between the vaccinated and unvaccinated patients. A total of 9428 (39.25%) patients were unvaccinated, and 14 588 (60.75%) patients had received at least one dose of the vaccine. Compared with the unvaccinated, the first, second, and third doses of vaccine resulted in 8%, 20%, and 33% lower risk of ICU mortality in the adjusted model, with risk ratio (RR): 0.92, 95% confidence interval (CI): 0.84–1.001, RR: 0.80, 95% CI: 0.77–0.83, and RR: 0.67, 95% CI: 0.64–0.71, respectively. The mean survival time was significantly shorter in the unvaccinated versus the fully vaccinated patients (hazard ratio [HR]: 0.84, 95% CI: 0.80–0.88); p < 0.001). All vaccine platforms successfully decreased the hazard of ICU death compared with the unvaccinated group. The duration of ICU stay was significantly shorter in the fully vaccinated than in unvaccinated group (MD, −0.62, 95% CI: −0.82 to −0.42; p < 0.001). Since COVID‐19 vaccination in all doses and platforms has been able to reduce the risk of mortality and length of ICU‐stay, universal vaccination is recommended based on vaccine availability.

show abstract

Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre

Cited by 5 publications

References 23 publications

Assessment of Clinical Profile and Treatment Outcome in Vaccinated and Unvaccinated SARS-CoV-2 Infected Patients

Assessment of Clinical Profile and Treatment Outcome in Vaccinated and Unvaccinated SARS-CoV-2 Infected Patients

Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy

Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran

Contact Info

Product

Resources

About